NCT07178795View on ClinicalTrials.gov

A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

440

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG

BL-M07D1

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Pembrolizumab

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Pemetrexed

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Carboplatin

Administration by intravenous infusion for a cycle of 3 weeks.

DRUG

Cisplatin

Administration by intravenous infusion for a cycle of 3 weeks.

All Listed Sponsors

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY